AmideBio receives grant to advance work on hyperinsulinism

BOULDER — AmideBio LLC, a biopharmaceutical company in Boulder that makes peptides used in research to discover therapies for diabetes, has received a $338,387 grant that it will use to further develop a treatment for hyperinsulinism.

Hyperinsulinism is a disease in which infants and newborn babies suffer from persistent hypoglycemia, or low blood-sugar levels, that can lead to seizures and brain damage.

AmideBio received the two-year grant from the National Institute of Health through a Small Business Innovation Research grant.

“This grant will allow us to further develop and test AmideBio’s stable glucagons for treatment…